338 related articles for article (PubMed ID: 21393609)
1. Accelerated drug approval: FDA may get tougher; companies cite hurdles.
Goozner M
J Natl Cancer Inst; 2011 Mar; 103(6):455-7. PubMed ID: 21393609
[No Abstract] [Full Text] [Related]
2. Investigational drug access taken to task in lawsuit against FDA.
Randal J
J Natl Cancer Inst; 2003 Dec; 95(24):1818-20. PubMed ID: 14679146
[No Abstract] [Full Text] [Related]
3. Early accelerated approval for highly targeted cancer drugs.
Chabner BA
N Engl J Med; 2011 Mar; 364(12):1087-9. PubMed ID: 21428763
[No Abstract] [Full Text] [Related]
4. TransMolecular receives FDA approval for 131-I-TM-601 IND application.
Expert Rev Anticancer Ther; 2002 Apr; 2(2):139. PubMed ID: 12113233
[No Abstract] [Full Text] [Related]
5. Neoadjuvant trials could speed up drug approvals.
Peres J
J Natl Cancer Inst; 2014 Mar; 106(3):dju072. PubMed ID: 24610911
[No Abstract] [Full Text] [Related]
6. First new lupus drug approved in half-century.
Thompson CA
Am J Health Syst Pharm; 2011 Apr; 68(8):646. PubMed ID: 21460166
[No Abstract] [Full Text] [Related]
7. FDA accelerated approval benefits glioblastoma.
Cloughesy T
Lancet Oncol; 2010 Dec; 11(12):1120. PubMed ID: 21126686
[No Abstract] [Full Text] [Related]
8. Biotech firm faces challenges from FDA, falling stock prices.
Reynolds T
J Natl Cancer Inst; 2002 Mar; 94(5):326-8. PubMed ID: 11880468
[No Abstract] [Full Text] [Related]
9. Changing end points in breast-cancer drug approval--the Avastin story.
D'Agostino RB
N Engl J Med; 2011 Jul; 365(2):e2. PubMed ID: 21707384
[No Abstract] [Full Text] [Related]
10. Promising drug is victim of bad business.
Dove A
Nat Med; 2002 Mar; 8(3):199. PubMed ID: 11875472
[No Abstract] [Full Text] [Related]
11. StatBite: FDA oncology drug product approvals in 2009.
J Natl Cancer Inst; 2010 Feb; 102(4):219. PubMed ID: 20145211
[No Abstract] [Full Text] [Related]
12. A note on breast cancer trials with pCR-based accelerated approval.
Xia Y; Cui L; Yang B
J Biopharm Stat; 2014; 24(5):1102-14. PubMed ID: 24926729
[TBL] [Abstract][Full Text] [Related]
13. The Ethical Challenges of Compassionate Use.
Caplan AL; Ray A
JAMA; 2016 Mar; 315(10):979-80. PubMed ID: 26868205
[No Abstract] [Full Text] [Related]
14. Expanded Access to Investigational Drugs: What Physicians and the Public Need to Know about FDA and Corporate Processes.
Finkelstein PE
AMA J Ethics; 2015 Dec; 17(12):1142-6. PubMed ID: 26698587
[No Abstract] [Full Text] [Related]
15. Accelerated approval regulations may need overhaul, panel suggests.
Finkelstein JB
J Natl Cancer Inst; 2005 Dec; 97(24):1802-4. PubMed ID: 16368938
[No Abstract] [Full Text] [Related]
16. Cetuximab approved by FDA for treatment of head and neck squamous cell cancer.
Cancer Biol Ther; 2006 Apr; 5(4):340-2. PubMed ID: 16808060
[No Abstract] [Full Text] [Related]
17. The FDA approves drugs for colorectal cancer, lung cancer.
FDA Consum; 2007; 41(1):5. PubMed ID: 17354284
[No Abstract] [Full Text] [Related]
18. Oncologic drugs advisory committee recommends withdrawing approval for bevacizumab use in breast cancer treatment.
Future Oncol; 2010 Sep; 6(9):1374. PubMed ID: 20931736
[No Abstract] [Full Text] [Related]
19. FDA increases focus on postmarketing studies.
Goozner M
J Natl Cancer Inst; 2010 Sep; 102(17):1302-4. PubMed ID: 20739650
[No Abstract] [Full Text] [Related]
20. Like raising a child.
Berger MS
J Clin Oncol; 2012 Apr; 30(10):1140-1. PubMed ID: 22253464
[No Abstract] [Full Text] [Related]
[Next] [New Search]
